GlassScriptPhysician profile
Melissa A Johnston
NPI 1851794374
$4,551.83
in general payments reported to CMS, 2019-2025
25 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $988 · 2022: $1,350 · 2023: $1,009 · 2024: $986 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,213.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $899.32 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $393.09 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Otsuka America Pharmaceutical, INC. | $389.83 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $360.45 | 2022-2024 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $304.47 | 2021-2024 | Ingrezza |
| Glaxosmithkline, LLC. | $302.04 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $291.80 | 2022-2024 | Caplyta |
| Indivior INC. | $236.49 | 2022-2024 | Perseris |
| Vanda Pharmaceuticals INC. | $222.70 | 2021-2024 | Fanapt, Hetlioz |
| Astrazeneca Pharmaceuticals LP | $207.33 | 2021-2025 | Airsupra, Farxiga |
| Gilead Sciences, INC. | $152.22 | 2021-2023 | |
| Axsome Therapeutics, INC. | $128.92 | 2022-2025 | Auvelity |
| Esperion Therapeutics, INC. | $124.99 | 2021 | |
| Alkermes, INC. | $97.66 | 2022-2025 | Aristada, Lybalvi |
| Lilly USA, LLC | $83.99 | 2021-2025 | Mounjaro, Zepbound |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $66.73 | 2023-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $45.54 | 2024 | Trintellix |
| Eisai INC. | $44.33 | 2021 | |
| Depuy Synthes Sales INC. | $43.46 | 2023 | Teligen |
| Tris Pharma INC | $36.44 | 2023 | Dyanavel Xr |
| Novo Nordisk INC | $34.28 | 2021-2025 | Wegovy |
| Abbott Laboratories | $31.43 | 2024 | Gallant |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.66 | 2023-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $13.18 | 2022 | |
| Corium, LLC | $12.48 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.